Comparative Pharmacology
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus FOSAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus FOSAMAX.
ETIDRONATE DISODIUM vs FOSAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, suppressing crystal dissolution and reducing bone turnover.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
Paget disease: 5-10 mg/kg/day orally, given as a single dose or divided every 12 hours, for up to 6 months; or 300 mg intravenously over at least 2 hours daily for 3 days. Heterotopic ossification: 20 mg/kg/day orally for 2 weeks pre- and 12 weeks post-surgery. Hypercalcemia of malignancy: 7.5 mg/kg intravenously over 4 hours daily for 3-7 days.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
None Documented
None Documented
Terminal half-life: 1-6 hours after single dose; prolonged to up to 2 weeks in bone due to slow release from hydroxyapatite.
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Renal: 30-50% of absorbed dose excreted unchanged in urine; biliary/fecal: minimal, with approximately 5% excreted in feces.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Category C
Category C
Bisphosphonate
Bisphosphonate